Eli Lilly and Novo Nordisk’s Obesity Moat Just Got Stronger
The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...
Novo Nordisk A/S (NVO): A Bull Case Theory
We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will ...
Why Novo Nordisk A/S (NVO) Is the Best ADR Stock to Invest in?
We recently published a list of 12 Best ADR Stocks To Invest In According to Analysts. In this article, we are going to take ...
Weight-loss drugs are everywhere, but how many Aussies are actually taking them?
A new class of weight-loss drugs touted as a revolutionary breakthrough in obesity management have received global attention, ...
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?
The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...